Disposal of Fazol G

Sinclair IS Pharma plc

Disposal of Fazol G

LONDON - March 18, 2013 - Sinclair IS Pharma plc (AIM: SPH.L), ("Sinclair IS") the international specialty pharmaceutical company, announces the disposal of Fazol G for a cash consideration of €1.15 million to Laboratoires Majorelle a French company specializing in the therapy area of gynaecology. Fazol G is used in the treatment of fungal infections and forms part of the Fazol brand family. Fazol G generated revenues of £0.4 million in the last full financial year to 30th June 2012, 15% of overall revenues of the Fazol brand.

The disposal is in line with the Board's strategy that planned non-core product disposals would finance a significant part of the €1.7 million redundancy and outplacement costs that arise on the closure of the French factory. Sinclair IS has now covered all these costs from the proceeds of non-core product disposals in the current financial year.

Ends

For further information please contact:

Sinclair IS Pharma plc Tel: +44 (0) 20 7467 6920

Chris Spooner

Alan Olby

Robert Taylor

Peel Hunt LLP Tel: +44 (0) 20 7418 8900

James Steel

Vijay Barathan

Notes to Editors:

About Sinclair IS Pharma plc - www.sinclairispharma.com 

Sinclair IS Pharma is an international specialty pharmaceutical company centred on Dermatology; in particular Aesthetics, Wound care, and Skin care. The group has a direct sales and marketing presence in the top five European markets and a rapidly growing International division concentrated on the Emerging Markets through long term multi-product, multi-country, sales, marketing and distribution deals with key strategic partners.